Targets › ABCB5
1 program from 1 company in 3 trials: 3 Phase 3; Cardiovascular, Other; next expected readout Jan 2027.
Energy-dependent efflux transporter responsible for decreased drug accumulation in multidrug-resistant cells. Specifically present in limbal stem cells, where it plays a key role in corneal development and repair (By similarity). (UniProt, Q2M3G0)
Open in Phaseline: the race on ABCB5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| RHEACELL GmbH & Co. KG | allo-APZ2-OTS Allogeneic ABCB5-positive dermal mesenchymal stromal cells | ABCB5 | Phase 3 | Epidermolysis Bullosa; Venous Leg Ulcer | Jan 2027 |
Epidermolysis Bullosa (2) Venous Leg Ulcer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.